Rivoceranib, a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), has been shown to reverse ABCB1- and ABCG2-mediated resistance in cancer cells [30,31]. This evidence concerns the gene ABCG2 and cancer.